Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice

Parasitology Research

Volumn 113, Issue 3, 2014, Pages 1195-1200

  Le, Loc ^a   Zhang, Weidong ^a   Karmakar, Souvik ^a   Ahmad, Gul ^b   Torben, Workineh ^c   Siddiqui, Afzal A ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b PERU STATE COLLEGE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PRIMER DNA; PROTEIN P80;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HELMINTHIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; UPREGULATION;

ANIMALIA; MUS; SCHISTOSOMA MANSONI;

ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HELMINTH PROTEINS; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; PARASITE EGG COUNT; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SPLEEN; VACCINATION; VACCINES, DNA;

EID: 84895516079     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-014-3757-4     Document Type: Article

References (28)

1. Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Kennedy RC, Siddiqui AA (2009a) Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 27:2830-2837
2. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA (2009b) Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 105:1767-1777
3. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, White GL, Carey DW, Mwinzi PN, Ganley-Leal L, Kennedy RC, Siddiqui AA (2011) Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 204:1437-1449
4. Bergquist R (1990) Prospects of vaccination against schistosomiasis. Scand J Infect Dis Suppl 76:60-71
5. Bergquist R, Al-Sherbiny M, Barakat R, Olds R (2002) Blueprint for schistosomiasis vaccine development. Acta Trop 82:183-192
6. Bergquist R, Utzinger J, McManus DP (2008) Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2:e244
7. 'Dara AA, Skelly PJ, Walker CM, Harn DA (2003) A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite Immunol 25:429-437
8. El Ridi R (1998) More on the search for a schistosomiasis vaccine. Parasitol Today 14:436
9. Junqueira-Kipnis AP, de Oliveira FM, Trentini MM, Tiwari S, Chen B, Resende DP, Silva BD, Chen M, Tesfa L, Jacobs WR Jr, Kipnis A (2013) Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis. PLoS One 8:e78639
10. Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21:346-351
11. Lu M, Xia ZY, Bao L (2013) Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy. Cell Immunol 285:111-117
12. Lustigman S, Prichard RK, Gazzinelli A, Grant WN, Boatin BA, McCarthy JS, Basanez MG (2012) A research agenda for helminth diseases of humans: the problem of helminthiases. PLoS Negl Trop Dis 6:e1582
13. McManus DP, Loukas A (2008) Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21:225-242
14. Nyindo M, Farah IO (1999) The baboon as a non-human primate model of human schistosome infection. Parasitol Today 15:478-482
15. Prichard RK, Basanez MG, Boatin BA, McCarthy JS, Garcia HH, Yang GJ, Sripa B, Lustigman S (2012) A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis 6:e1549
16. Radosevic K, Rodriguez A, Lemckert A, Goudsmit J (2009) Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 8:577-592
17. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuente LA, Garba A, Mohammed KA, Schur N, Person B, Colley DG, Utzinger J (2013) Time to set the agenda for schistosomiasis elimination. Acta Trop 128:423-440
18. Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, Dekaban GA, Clarke MW (1993) Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1181:37-44
19. Siddiqui AA, Ahmad G, Damian RT, Kennedy RC (2008) Experimental vaccines in animal models for schistosomiasis. Parasitol Res 102:825-833
20. Siddiqui AA, Siddiqui BA, Ganley-Leal L (2011) Schistosomiasis vaccines. Hum Vaccin 7:1192-1197
21. Tallima H, Salah M, Guirguis FR, El RR (2009) Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. Cytokine 48:239-245
22. Terer CC, Bustinduy AL, Magtanong RV, Muhoho N, Mungai PL, Muchiri EM, Kitron U, King CH, Mutuku FM (2013) Evaluation of the health-related quality of life of children in schistosoma haematobium-endemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 7:e2106
23. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA (2007) Immunopathology of schistosomiasis. Immunol Cell Biol 85:148-154
24. Young BW, Podesta RB (1986) Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni. J Parasitol 72:802-803
25. Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Podesta RB, Kennedy RC, Siddiqui AA (2010a) Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 201:1105-1112
26. Zhang W, Ahmad G, Torben W, Siddiqui AA (2010b) Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 32:252-258
27. Zhang W, Ahmad G, Torben W, Siddiqui AA (2011) Schistosoma mansoni antigen Sm-p80: prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 118:142-151
28. Zhou Y, Podesta RB (1989) Effects of serotonin (5HT) and complement C3 on the synthesis of the surface membrane precursors of adult Schistosoma mansoni. J Parasitol 75:333-343